available by October 2020

available by September 2020

available by September 2020

available by September 2020

The introduction of biosimilar medicines has had a significant impact on the reshaping of the Access Landscape wherever they are used. Over two days we will cover the contribution of biosimilar medicines to Broader Access, Earlier Access and Future Access.

The benefits already realised, thanks to the existing biosimilar regulatory and access policy frameworks in the EU, have materialised in greater access equity with undeniably Broader and Earlier Access to biological medicines in all countries, although the extent remains variable. Leveraging on this, discussions will focus on how to build healthy systems for healthier communities. A number of practical and concrete perspectives from stakeholders will illustrate policy intervention examples from different EU member states and the therapy area, including a deep dive into experience garnered in the field of rheumatology.

Beyond supporting efficiency gains and greater equity within today’s healthcare systems, we will hold a multi-stakeholder reflection and debate on what would be the ideal stepping stones to foster Future Access to biosimilar medicines, referencing the biologic originator portfolio losing exclusivity between now and 2030.

As a key point in the health equity policy agenda, this 18th edition aims at providing a lively and interactive forum where important milestones are reached and acknowledged, the synergies facilitated and the future needs collectively reflected upon.

During these two interactive days, leaders and world experts in biosimilar medicines will gather and debate the evolving biosimilar medicines landscape and new trends. Discussion will focus on setting aims and implementing good practices to achieve the depth, breadth and speed of the use of biosimilar medicines as a lever to realise the access benefits.

The various sessions will cover all relevant areas of healthcare policy, market access, scientific developments, regulatory and clinical experience.

Join us and have your say!

As a participant in this event, you will

  • interact openly with thought leaders in the field
  • engage in vibrant discussions with the full spectrum of healthcare stakeholders, policy makers and industry
  • deepen your knowledge on the latest regulatory and scientific hot topics
  • comprehend the impact that upcoming policy frameworks will have on access to standards of care and competition in the biologics market

Our programme highlights include

  • Transforming healthcare policies for healthy communities
  • Zooming in on European health systems: access equity and healthy competition
  • Redesigning Practices in Rheumatology with the introduction of biosimilar medicines
  • Creating synergies: how can regulators help towards greater access to biological treatment?
  • EU & US Biosimilar regulatory policy developments
  • Biosimilar medicines of orphan biologics: future pipeline

See here the companies/organisations present at the 2019 edition!


Medicines for Europe is honored to be collaborating with the following partners to make this year’s conference



Lucia Romagnoli
M: +44 (0) 7 562 87 68 73

For more information on advertising, exhibition and sponsorship packages:
Trudy Beks
M: +31 6 4119 0824

Media Requirements and Press Policy
For any other media enquiries:
Kate O’Regan
P: +32 (0)2 239 2019